secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001493152-22-005892
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics acquires lab assets from ResearchDx for up to $6.2M, launches LucidDx Labs; CMO resigns
--------------------------------------------------------------------------------

- LucidDx Labs acquired licenses/assets from ResearchDx for up to $6.2M; $1.0M cash upfront, remainder contingent on license transfers and earnout.
- LucidDx Labs will operate its own CLIA/CAP lab in Lake Forest, CA to perform EsoGuard testing, replacing RDx as testing provider.
- LucidDx Labs entered a 3-year MSA with RDx for up to $1.8M in quarterly installments, plus lease at $71,465/month for lab space.
- CMO David F. Wurtman resigned effective March 31, 2022; Brian J. deGuzman, MD (current Chief Compliance Officer) will assume duties.
- Earnout payments may be made in cash or newly issued LUCD stock, not exceeding 19.99% of outstanding shares, exempt from registration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315222005892/0001493152-22-005892-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315222005892/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-005892

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer